Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mallinckrodt Medical

This article was originally published in The Gray Sheet

Executive Summary

Forms alliance with OPTIMEDx to develop optical imaging agents for detection and localization of cancer cells. Seattle-based OPTIMEDx is developing a light-based imaging technology "designed to improve the detection and definition of certain cancer cells at an early stage," the companies said. Mallinckrodt will make an equity investment in OPTIMEDx, milestone payments, and product royalties. The company gains exclusive rights "to develop optical imaging agents for mammography" and non-exclusive rights to develop other cancer imaging agents



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts